Drug Reduces Airway Mucus In Preclinical Asthma Model

Inverseon, Inc.
announces the publication of a
rapid communication of groundbreaking research led by
Professor Richard Bond of the University of Houston,
Inverseon's Scientific Founder. In the March article by
Nguyen, et. al., in the American Journal of Respiratory Cell
and Molecular Biology 2008; 38: 256-262, entitled, "Chronic
Exposure to Beta-Blockers Attenuates Inflammation and Mucin
Content in a Murine Asthma Model," airway mucus
hypersecretion and inflammation were almost completely
reversed upon treatment with certain beta blockers. The
Journal commented that, "This research may result in a
paradigm shift in the treatment of asthma. This research
demonstrates the importance that duration of therapy has on
clinical and physiologic responses."



"It is gratifying to see these findings, which were
originally described in Prof. Bond's laboratory, confirmed
in a respected independent laboratory," commented William J.
Garner, MD, Chairman of Inverseon.



About Inverseon, Inc.



Inverseon's product development programs target significant
unmet medical needs and major market opportunities in
chronic pulmonary diseases such as asthma, COPD and
pulmonary hypertension. Inverseon was founded based on the
original work of Prof. Richard Bond of the University of
Houston. Professor Bond termed the effects "Paradoxical
Pharmacology," based on the divergence of acute versus
chronic effects of certain drugs in chronic diseases. For
further information, please visit Inverseon's website at
inverseon.



Forward-Looking Statement



This press release may contain forward-looking statements.
In some cases, you can identify forward-looking statements
by terminology such as "may," "will," "should," "expect,"
"plan," "anticipate," "believe," "estimate," "predict,"
"potential" or "continue," the negative of such terms, or
other comparable terminology. These statements are only
predictions. Although we believe that the expectations
reflected in the forward-looking statements are reasonable,
such statements should not be regarded as a representation
by the Company, or any other person, that such
forward-looking statements will be achieved. We undertake no
duty to update any of the forward-looking statements,
whether as a result of new information, future events, or
otherwise. In light of the foregoing, readers are cautioned
not to place undue reliance on such forward-looking
statements.

Inverseon, Inc.